Literature DB >> 25627860

Association of inpatient and outpatient glucose management with inpatient mortality among patients with and without diabetes at a major academic medical center.

Neel M Butala1, Benjamin K Johnson, James D Dziura, Jesse S Reynolds, Janis E Bozzo, Thomas J Balcezak, Silvio E Inzucchi, Leora I Horwitz.   

Abstract

BACKGROUND: Hospitalized patients with diabetes have experienced a disproportionate reduction in mortality over the past decade.
OBJECTIVE: To examine whether this differential decrease affected all patients with diabetes, and to identify explanatory factors.
DESIGN: Serial, cross-sectional observational study.
SETTING: Academic medical center. PATIENTS: All adult, nonobstetric patients with an inpatient discharge between January 1, 2000 and December 31, 2010. MEASUREMENT: We assessed in-hospital mortality; inpatient glycemic control (percentage of hospital days with glucose below 70, above 299, and between 70 and 179 mg/dL, and standard deviation of glucose measurements), and outpatient glycemic control (hemoglobin A1c).
RESULTS: We analyzed 322,938 admissions, including 76,758 (23.8%) with diabetes. Among 54,645 intensive care unit (ICU) admissions, there was a 7.8% relative reduction in the odds of mortality in each successive year for patients with diabetes, adjusted for age, race, payer, length of stay, discharge diagnosis, comorbidities, and service (odds ratio [OR]: 0.923, 95% confidence interval [CI]: 0.906-0.940). This was significantly greater than the 2.6% yearly reduction for those without diabetes (OR: 0.974, 95% CI: 0.963-0.985; P < 0.001 for interaction). In contrast, the greater decrease in mortality among non-ICU patients with diabetes did not reach significance. Results were similar among medical and surgical patients. Among ICU patients with diabetes, the significant decline in mortality persisted after adjustment for inpatient and outpatient glucose control (OR: 0.953, 95% CI: 0.914-0.994).
CONCLUSIONS: Patients with diabetes in the ICU have experienced a disproportionate reduction in mortality that is not explained by glucose control. Potential explanations include improved cardiovascular risk management or advances in therapies for diseases commonly affecting patients with diabetes.
© 2015 Society of Hospital Medicine.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25627860      PMCID: PMC4390436          DOI: 10.1002/jhm.2321

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.960


  37 in total

1.  Intensive insulin therapy in the medical ICU.

Authors:  Greet Van den Berghe; Alexander Wilmer; Greet Hermans; Wouter Meersseman; Pieter J Wouters; Ilse Milants; Eric Van Wijngaerden; Herman Bobbaers; Roger Bouillon
Journal:  N Engl J Med       Date:  2006-02-02       Impact factor: 91.245

2.  Is glycemic control improving in U.S. adults?

Authors:  Thomas J Hoerger; Joel E Segel; Edward W Gregg; Jinan B Saaddine
Journal:  Diabetes Care       Date:  2007-10-12       Impact factor: 19.112

3.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

Authors:  Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

4.  Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study.

Authors:  K Malmberg; A Norhammar; H Wedel; L Rydén
Journal:  Circulation       Date:  1999-05-25       Impact factor: 29.690

Review 5.  Coronary heart disease in patients with diabetes: part II: recent advances in coronary revascularization.

Authors:  Colin Berry; Jean-Claude Tardif; Martial G Bourassa
Journal:  J Am Coll Cardiol       Date:  2007-01-26       Impact factor: 24.094

6.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.

Authors:  Anushka Patel; S MacMahon; J Chalmers; B Neal; M Woodward; L Billot; S Harrap; N Poulter; M Marre; M Cooper; P Glasziou; D E Grobbee; P Hamet; S Heller; L S Liu; G Mancia; C E Mogensen; C Y Pan; A Rodgers; B Williams
Journal:  Lancet       Date:  2007-09-08       Impact factor: 79.321

7.  Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD.

Authors:  D M Mannino; D Thorn; A Swensen; F Holguin
Journal:  Eur Respir J       Date:  2008-06-25       Impact factor: 16.671

8.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

9.  Type 2 diabetes and pneumonia outcomes: a population-based cohort study.

Authors:  Jette B Kornum; Reimar W Thomsen; Anders Riis; Hans-Henrik Lervang; Henrik C Schønheyder; Henrik T Sørensen
Journal:  Diabetes Care       Date:  2007-06-26       Impact factor: 19.112

10.  The role of body mass index and diabetes in the development of acute organ failure and subsequent mortality in an observational cohort.

Authors:  Katarina Slynkova; David M Mannino; Greg S Martin; Richard S Morehead; Dennis E Doherty
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.